HQ Team
December 5, 2024: Amgen Inc., a US biotechnology company, will set up a second drug manufacturing facility in North Carolina for $1 billion, according to a company statement.
The company, headquartered in Thousand Oaks, California, has already invested $550 million in an existing facility in North California.
“This expansion underscores our unwavering focus on bringing transformative medicines to patients around the world,” said Robert A. Bradway, chairman and chief executive officer at Amgen.
“North Carolina will be an important part of our global manufacturing network as we continue to meet the growing demand for our innovative therapies while generating significant local economic impact,” he said.
Expand manufacturing network
The $1 billion facility aligns with Amgen’s “commitment to environmental stewardship and manufacturing excellence,” according to the statement.
The expansion enhances the company’s global biomanufacturing network, leveraging operational expertise and technological advancements to ensure the reliable and efficient delivery of high-quality medicines to patients worldwide.
Amgen is engaged in the discovery, development and manufacturing of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. It was formerly known as Applied Molecular Genetics Inc.
In October 2023, Amgen Inc., a US biotechnology company, completed the acquisition of Horizon Therapeutics Plc for $27.8 billion, gaining access to the Dublin-based firm’s two drugs that treat rare inflammatory diseases.
